1. Alcoholic-Hepatitis, Links to Brain and Microbiome: Mechanisms, Clinical and Experimental Research.
- Author
-
Neuman, Manuela G, Seitz, Helmut Karl, French, Samuel W, Malnick, Stephen, Tsukamoto, Heidekazu, Cohen, Lawrence B, Hoffman, Paula, Tabakoff, Boris, Fasullo, Michael, Nagy, Laura E, Tuma, Pamela L, Schnabl, Bernd, Mueller, Sebastian, Groebner, Jennifer L, Barbara, French A, Yue, Jia, Nikko, Afifiyan, Alejandro, Mendoza, Brittany, Tillman, Edward, Vitocruz, Harrall, Kylie, Saba, Laura, and Mihai, Opris
- Subjects
CYP 1A2 ,CYP2E1 ,acetaldehyde dehydrogenase (ALDH) ,alcohol dehydrogenase (ADH) ,CYP 1A1 ,alcoholic hepatitis ,hepato-carcinogenesis ,hepatocytotoxicity ,his3-Δ3′ and his3- Δ5′ ,laboratory markers ,microsomal ethanol oxidizing system (MEOS) ,immunohistochemistry ,mithocondrion ,acetaldehyde dehydrogenase ,alcohol dehydrogenase ,CYP 1A1 ,his3-Delta 3 ' and his3- Delta 5 ' ,microsomal ethanol oxidizing system ,immunohistochemistry - Abstract
The following review article presents clinical and experimental features of alcohol-induced liver disease (ALD). Basic aspects of alcohol metabolism leading to the development of liver hepatotoxicity are discussed. ALD includes fatty liver, acute alcoholic hepatitis with or without liver failure, alcoholic steatohepatitis (ASH) leading to fibrosis and cirrhosis, and hepatocellular cancer (HCC). ALD is fully attributable to alcohol consumption. However, only 10-20% of heavy drinkers (persons consuming more than 40 g of ethanol/day) develop clinical ALD. Moreover, there is a link between behaviour and environmental factors that determine the amount of alcohol misuse and their liver disease. The range of clinical presentation varies from reversible alcoholic hepatic steatosis to cirrhosis, hepatic failure, and hepatocellular carcinoma. We aimed to (1) describe the clinico-pathology of ALD, (2) examine the role of immune responses in the development of alcoholic hepatitis (ASH), (3) propose diagnostic markers of ASH, (4) analyze the experimental models of ALD, (5) study the role of alcohol in changing the microbiota, and (6) articulate how findings in the liver and/or intestine influence the brain (and/or vice versa) on ASH; (7) identify pathways in alcohol-induced organ damage and (8) to target new innovative experimental concepts modeling the experimental approaches. The present review includes evidence recognizing the key toxic role of alcohol in ALD severity. Cytochrome p450 CYP2E1 activation may change the severity of ASH. The microbiota is a key element in immune responses, being an inducer of proinflammatory T helper 17 cells and regulatory T cells in the intestine. Alcohol consumption changes the intestinal microbiota and influences liver steatosis and liver inflammation. Knowing how to exploit the microbiome to modulate the immune system might lead to a new form of personalized medicine in ALF and ASH.
- Published
- 2020